1.  3
    Rethinking success, integrity, and culture in research (part 2) — a multi-actor qualitative study on problems of science.Wim Pinxten & Noémie Aubert Bonn - 2021 - Research Integrity and Peer Review 6 (1).
    BackgroundResearch misconduct and questionable research practices have been the subject of increasing attention in the past few years. But despite the rich body of research available, few empirical works also include the perspectives of non-researcher stakeholders.MethodsWe conducted semi-structured interviews and focus groups with policy makers, funders, institution leaders, editors or publishers, research integrity office members, research integrity community members, laboratory technicians, researchers, research students, and former-researchers who changed career to inquire on the topics of success, integrity, and responsibilities in science. (...)
    No categories
    Direct download  
    Export citation  
    Bookmark   3 citations  
  2.  33
    Ethical framework for the detection, management and communication of incidental findings in imaging studies, building on an interview study of researchers’ practices and perspectives.Eline M. Bunnik, Lisa van Bodegom, Wim Pinxten, Inez D. de Beaufort & Meike W. Vernooij - 2017 - BMC Medical Ethics 18 (1):10.
    As thousands of healthy research participants are being included in small and large imaging studies, it is essential that dilemmas raised by the detection of incidental findings are adequately handled. Current ethical guidance indicates that pathways for dealing with incidental findings should be in place, but does not specify what such pathways should look like. Building on an interview study of researchers’ practices and perspectives, we identified key considerations for the set-up of pathways for the detection, management and communication of (...)
    Direct download (8 more)  
    Export citation  
    Bookmark   5 citations  
  3.  9
    The Impact of Incidental Findings Detected During Brain Imaging on Research Participants of the Rotterdam Study: An Interview Study.Charlotte H. C. Bomhof, Lisa van Bodegom, Meike W. Vernooij, Wim Pinxten, Inez D. de Beaufort & Eline M. Bunnik - 2020 - Cambridge Quarterly of Healthcare Ethics 29 (4):542-556.
    This interview study investigates the short- and long-term implications of incidental findings detected through brain imaging on research participants’ lives and their surroundings. For this study, nine participants of the Rotterdam Scan Study with an incidental finding were approached and interviewed. When examining research participants’ narratives on the impact of the disclosure of incidental findings, the authors identified five sets of tensions with regard to motivations for and expectations of research participation, preferences regarding disclosure, short- and long-term impacts and impacts (...)
    Direct download (2 more)  
    Export citation  
    Bookmark   1 citation  
  4.  16
    Regulating trust in pediatric clinical trials.Wim Pinxten, Herman Nys & Kris Dierickx - 2008 - Medicine, Health Care and Philosophy 11 (4):439-444.
    The participation of minors in clinical trials is essential to provide safe and effective medical care to children. Because few drugs have been tested in children, pediatricians are forced to prescribe medications off-label with uncertain efficacy and safety. In this article, we analyze how the enrollment of minors in clinical trials is negotiated within relationships of mutual trust between clinicians, minors, and their parents. After a brief description of the problems associated with involving minors in clinical research, we consider how (...)
    Direct download (3 more)  
    Export citation  
    Bookmark   4 citations  
  5.  34
    A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation: Figure 1.Wim Pinxten, Yvonne Denier, Marc Dooms, Jean-Jacques Cassiman & Kris Dierickx - 2012 - Journal of Medical Ethics 38 (3):148-153.
    For a significant number of patients, there exists no, or only little, interest in developing a treatment for their disease or condition. Especially with regard to rare diseases, the lack of commercial interest in drug development is a burning issue. Several interventions have been made in the regulatory field in order to address the commercial disinterest in these conditions. However, existing regulations mainly focus on the provision of incentives to the sponsors of clinical trials of orphan drugs, and leave unanswered (...)
    Direct download (6 more)  
    Export citation  
    Bookmark   2 citations  
  6.  5
    Quality of medicines in resource-limited settings: need for ethical guidance.Raffaella Ravinetto, Wim Pinxten & Lembit Rägo - 2018 - Global Bioethics 29 (1):81-94.
    ABSTRACTThe quality of medicines is generally adequately assured by manufacturers and regulatory authorities for well-resourced settings, while the implementation of existing quality standards is challenged in many low- and middle-income countries. This situation of multiple pharmaceutical standards raises the question whether it could ever be ethically justified to compromise on the quality assurance of medicines depending on what individuals, communities, or societies can afford. In this paper, we contend that ethically, any unjustified exceptions to medicines’ quality assurance represents a violation (...)
    No categories
    Direct download (6 more)  
    Export citation  
    Bookmark   1 citation  
  7.  6
    Never Look a Gift Horse in the Mouth? Four Reasons Not to Blur the Line Between Research and Care in Low- and Middle-Income Countries.Wim Pinxten, Raffaella Ravinetto & Anne Buvé - 2016 - American Journal of Bioethics 16 (6):17-19.
  8.  15
    Ethical and regulatory issues in pediatric research supporting the non-clinical application of fmr imaging.Wim Pinxten, Herman Nys & Kris Dierickx - 2009 - American Journal of Bioethics 9 (1):21 – 23.
    Direct download (4 more)  
    Export citation